Depression among Medical Students of a Medical College in Nepal during COVID-19 Pandemic: A Descriptive Cross-sectional Study


Posted: 2021-09-11 19:00:00
Introduction: Depression is a common mental disorder. Medical school is a stressful environment. The outbreak of COVID-19 has added to the plight of medical students. This study was conducted to determine the prevalence of depression among medical students of a medical college in Nepal during the COVID-19 pandemic. Methods: A descriptive cross-sectional study was conducted among medical students of a medical college in Nepal from August 2020 to September 2020. The sample size of our study was 223. A convenient sampling method was adopted for the selection of respondents. The study was approved by the Institutional Review Committee (Reference no:321). The data were analyzed using Statistical Package for Social Sciences version 22. Point estimate at 95% Confidence Interval was calculated along with frequency and proportion for binary data. The study instrument consisted of the Patient Health Questionnaire and socio-demographic information. Results: Out of 223 participants, the prevalence of depression was seen among 52 (23.3%) (17.7%-28.9% at 95% Confidence Interval) students in our study. Among them, 25 (48.1%) females and 27 (51.9%) males were depressed. The prevalence of depression was higher in preclinical years (first and second year) than in clinical years (third, fourth and final year). Conclusions: The prevalence of depression among medical students in Nepal during the pandemic was less than the findings of similar studies conducted in Nepal before the pandemic. Further studies are required to get more knowledge about the factors associated with mental health of medical students.

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
4月 21, 2020 バイオアソシエイツ

Gilead社は調査中の化合物RemdesivirのCOVID-19に対する進捗を更新

Gilead Sciences社は、世界の保健当局と緊密に協力して、調査用化合物「Remdesivir(レムデシビル)」(画像)の実験的使用を通じ、新型コロナウイルス( COVID-19 )に対応していることを報告した。米国食品医薬品局(FDA)、疾病対策センター(CDC)、保健福祉省(DHHS)、米国立アレルギー感染症研究所(NIAID)、国防総省(DoD)- CBRN Medical、中国CDCおよび国家医療製品管理局(NMPA)、世界保健機関(WHO)、そして個々の研究者と臨床医と共同して、Gilead…